What clinicians believe they said and what patients believe they heard

New drugs for relapsed and refractory Hodgkin's lymphoma

How malignant cells in patients with CLL escape T-cell recognition

Reducing radiotherapy for Hodgkin's lymphoma while maintaining the highest cure rate

Impressive results with a bispecific antibody for ALL

Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)

Early phase trial of ibrutinib for chronic lymphocytic leukaemia

Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease

How malignant cells in patients with CLL escape T-cell recognition

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma

Hodgkin Lymphoma focusing on reducing radiotherapy, while maintaining the highest possible cure rate

ASCO 2012: Advances in myeloma